Please login to the form below

Not currently logged in
Email:
Password:

GSK pulls application for HES treatment

The EU marketing application for an HES product has been withdrawn following clinical benefit concerns

GlaxoSmithKline (GSK) has withdrawn the marketing authorisation application in the EU for mepolizumab for the treatment of hypereosinophilic syndrome (HES), following feedback from the Committee for Medicinal Products for Human Use (CHMP) that additional data was needed to further demonstrate clinical benefits.

Mepolizumab, an investigational, humanised monoclonal antibody, was intended for the treatment of FIP1 negative HES (HES patients without the FIPL1-PDGRA fusion gene), to reduce or eliminate the need for corticosteroid therapy and to reduce eosinophil count. There are currently no approved therapies in the EU for FIP1 negative HES.

GSK plans to continue, where permitted, to support access to mepolizumab for patients with life-threatening HES through its ongoing compassionate use programme. Patients will receive the drug for as long as they and their doctor believe they are benefiting from the treatment.

"Research and development in HES is tremendously challenging," said David Gordon, VP Biopharm R&D at GSK. "It is a disease with very limited treatment options and this decision has been extremely difficult to take. Nevertheless, we are committed to exploring new options to develop mepolizumab as a treatment for HES," he added.

Withdrawal of the EU application for mepolizumab for the treatment of HES does not preclude GSK from filing an application at a later date and the company will continue to explore future options for the development of the product. Development programmes for the other potential indications, including severe asthma will continue as planned. 

30th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics